- Home
- MIRM vs MVSTW Comparison
MIRM vs MVSTW Comparison
Compare MIRM & MVSTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- MVSTW
- Stock Information
- Founded
- MIRM 2018
- MVSTW 2006
- Country
- MIRM United States
- MVSTW United States
- Employees
- MIRM N/A
- MVSTW 2006
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- MVSTW Industrial Machinery/Components
- Sector
- MIRM Health Care
- MVSTW Miscellaneous
- Exchange
- MIRM Nasdaq
- MVSTW Nasdaq
- Market Cap
- MIRM 1.9B
- MVSTW N/A
- IPO Year
- MIRM 2019
- MVSTW N/A
- Fundamental
- Price
- MIRM $40.00
- MVSTW $0.23
- Analyst Decision
- MIRM Strong Buy
- MVSTW
- Analyst Count
- MIRM 11
- MVSTW 0
- Target Price
- MIRM $58.55
- MVSTW N/A
- AVG Volume (30 Days)
- MIRM 447.2K
- MVSTW 126.0K
- Earning Date
- MIRM 05-07-2025
- MVSTW 03-14-2025
- Dividend Yield
- MIRM N/A
- MVSTW N/A
- EPS Growth
- MIRM N/A
- MVSTW N/A
- EPS
- MIRM N/A
- MVSTW N/A
- Revenue
- MIRM $336,888,000.00
- MVSTW $370,989,000.00
- Revenue This Year
- MIRM $29.51
- MVSTW N/A
- Revenue Next Year
- MIRM $20.27
- MVSTW N/A
- P/E Ratio
- MIRM N/A
- MVSTW N/A
- Revenue Growth
- MIRM 80.76
- MVSTW 39.03
- 52 Week Low
- MIRM $23.14
- MVSTW $0.35
- 52 Week High
- MIRM $54.23
- MVSTW $0.44
- Technical
- Relative Strength Index (RSI)
- MIRM 41.05
- MVSTW N/A
- Support Level
- MIRM $38.22
- MVSTW N/A
- Resistance Level
- MIRM $40.14
- MVSTW N/A
- Average True Range (ATR)
- MIRM 2.24
- MVSTW 0.00
- MACD
- MIRM 0.07
- MVSTW 0.00
- Stochastic Oscillator
- MIRM 48.50
- MVSTW 0.00
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About MVSTW Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extend from core battery chemistry to battery packs.